🚀 Vertex Pharmaceuticals (+22%) – Market cap hit $127 B on back-to-back approvals for once-daily CF triple Alyftrek (US Dec 2024, UK Mar 2025) and non-opioid pain pill Journavx, keeping its cystic-fibrosis engine roaring while diversifying into pain.
Share this post
📊 Large Pharma stock Q1 2025 👇
Share this post
🚀 Vertex Pharmaceuticals (+22%) – Market cap hit $127 B on back-to-back approvals for once-daily CF triple Alyftrek (US Dec 2024, UK Mar 2025) and non-opioid pain pill Journavx, keeping its cystic-fibrosis engine roaring while diversifying into pain.